肿瘤细胞治疗研究
英文原题：Biomarkers as targets for CAR-T/NK cell therapy in AML.
Biomarkers as targets for CAR-T/NK cell therapy in AML.
成人中最常见的急性白血病类型是急性髓系白血病（AML），其治疗通常采用诱导化疗方案，随后进行巩固治疗或异基因造血干细胞移植（HSCT）。
成人中最常见的急性白血病是急性髓系白血病（AML），其治疗通常采用诱导化疗方案，随后进行巩固治疗或异基因造血干细胞移植（HSCT）。然而，部分患者仍会发展为复发或难治性AML（R/R-AML）。小分子靶向药物需要长期给药。并非所有患者都携带分子靶点。因此，需要新型药物来改善治疗结局。近年来，已制备出以AML相关抗原为靶点的嵌合抗原受体（CAR）工程化T细胞和自然杀伤（NK）细胞，目前正在临床前和临床环境中进行测试。本综述概述了针对AML的CAR-T/NK治疗。
The most common kind of acute leukemia in adults is acute myeloid leukemia (AML), which is often treated with induction chemotherapy regimens followed by consolidation or allogeneic hematopoietic stem cell transplantation (HSCT). However, some patients continue to develop relapsed or refractory AML (R/R-AML). Small molecular targeted drugs require long-time administration. Not all the patients hold molecular targets. Novel medicines are therefore needed to enhance treatment outcomes. T cells and natural killer (NK) cells engineered with chimeric antigen receptors (CARs) that target antigens associated with AML have recently been produced and are currently being tested in both pre-clinical and clinical settings. This review provides an overview of CAR-T/NK treatments for AML.
MEMBER ACCOUNT
登录成功会直接打开下一页。
